Zoetis posts Q3 2026 results, narrows revenue guidance, raises EPS outlook

Zoetis Inc. reported third quarter 2026 results on November 5, 2026, with revenue of $2.4 billion, a decrease of 1% on a reported and organic operational basis compared with the third quarter of 2025¹. Net income was $591 million, down 18% on a reported basis, and diluted EPS was $1.44, down 12%.¹ Adjusted net income was $720 million, a 5% reported decline, while adjusted diluted EPS rose 3% to $1.75.¹

On the pipeline side, the company said it continued to advance innovation across its diversified portfolio and remains on track for expected 2026 product approvals, with some approvals previously anticipated for 2027 now expected in the fourth quarter of 2026¹. In October, Zoetis received FDA approval for Convenia RTU for Dogs, a long-acting antibacterial injection for dogs¹. The company called it the second major market approval this year, noting both approvals came ahead of their expected timelines¹, and said the product is expected to reach veterinarians in the first quarter of 2027¹.

Also during the quarter, Zoetis launched Lenivia for dogs in Great Britain and received Swiss approval for Portela for cats, both long-acting osteoarthritis pain treatments that can last up to three months per injection¹. Separately, Simparica Trio received a U.S. FDA Emergency Use Authorization for treating New World screwworm infestations in dogs and puppies, adding to Zoetis' existing response that includes Dectomax and Dectomax-CA1 for other species at risk¹.

On guidance, Zoetis narrowed full-year 2026 revenue guidance to $9.220 billion to $9.320 billion, implying organic operational growth of negative 2% to negative 1%, while raising adjusted net income guidance to $2.600 billion to $2.640 billion and adjusted diluted EPS guidance to $6.25 to $6.35¹.